Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Vaios HatzoglouJung Hun OhOlivia BuckXuling LinMichelle LeeAmita Shukla-DaveRobert J YoungKyung K PeckBehroze VachhaAndrei I HolodnyChristian Grommes

Published in: Journal of neuro-oncology (2018)

Pretreatment Vp and Ktrans derived from dynamic contrast-enhanced MRI may be novel prognostic quantitative imaging biomarkers of progression-free survival in patients with PCNSL. These data should be prospectively validated in larger patient cohorts.

Keyphrases

free survival
contrast enhanced
high resolution
magnetic resonance imaging
diffusion weighted imaging
diffuse large b cell lymphoma
computed tomography
big data
deep learning